These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 2526325)

  • 1. Inhibition of the pituitary-gonadal axis by a single intramuscular administration of D-Trp-6-LH-RH (decapeptyl) in a sustained-release formulation in patients with prostatic carcinoma.
    Gonzalez-Barcena D; Perez-Sanchez PL; Graef A; Gomez AM; Berea H; Comaru-Schally AM; Schally AV
    Prostate; 1989; 14(4):291-300. PubMed ID: 2526325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial with D-Trp-6-LH-RH in prostatic carcinoma: comparison with other hormonal agents.
    Mathé G; Schally AV; Comaru-Schally AM; Mauvernay RY; Vovan ML; Machover D; Misset JL; Court B; Bouchard P; Duchier J
    Prostate; 1986; 9(4):327-42. PubMed ID: 2947053
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Investigation of the combination of the agonist D-Trp-6-LH-RH and the antiandrogen flutamide in the treatment of Dunning R-3327H prostate cancer model.
    Redding TW; Schally AV
    Prostate; 1985; 6(3):219-32. PubMed ID: 3157927
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Somatostatin analogs as adjuncts to agonists of luteinizing hormone-releasing hormone in the treatment of experimental prostate cancer.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1987 Oct; 84(20):7275-9. PubMed ID: 2890164
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of prostatic cancers by periodic administration of a delayed-release preparation of D-Trp(6)-LHRH].
    Roger M; Duchier J; Lahlou N; Schally AV
    Ann Urol (Paris); 1986; 20(2):109-12. PubMed ID: 2424359
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Persistent blockade of the pituitary-gonadal axis in patients with prostatic carcinoma during chronic administration of D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Berea-Dominguez H; Graef-Sanchez A; Becerril-Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1986; 9(2):207-15. PubMed ID: 2944084
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Recovery of pituitary-gonadal function in male rats after long-term suppression induced by a single injection of microcapsules of LH-RH antagonist cetrorelix (SB-75).
    Pinski J; Yano T; Szepeshazi K; Groot K; Schally AV
    J Androl; 1993; 14(3):164-9. PubMed ID: 8407570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term results with a long-acting formulation of D-TRP-6 LH-RH in patients with prostate cancer: an Italian prostatic cancer project (P.O.N.CA.P.) study.
    Boccardo F; Decensi A; Guarneri D; Rubagotti A; Massa T; Martorana G; Giberti C; Cerruti GB; Tani F; Zanollo A
    Prostate; 1987; 11(3):243-55. PubMed ID: 2960957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination of a long-acting delivery system for luteinizing hormone-releasing hormone agonist with Novantrone chemotherapy: increased efficacy in the rat prostate cancer model.
    Schally AV; Kook AI; Monje E; Redding TW; Paz-Bouza JI
    Proc Natl Acad Sci U S A; 1986 Nov; 83(22):8764-8. PubMed ID: 2946045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of advanced prostatic carcinoma with D-Trp-6-LH-RH.
    Gonzalez-Barcena D; Perez-Sanchez P; Ureta-Sanchez S; Berea Dominguez H; Graef-Sanchez A; Becerril Morales M; Comaru-Schally AM; Schally AV
    Prostate; 1985; 7(1):21-30. PubMed ID: 2934692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sustained release formulations of luteinizing hormone-releasing hormone antagonist SB-75 inhibit proliferation and enhance apoptotic cell death of human prostate carcinoma (PC-82) in male nude mice.
    Redding TW; Schally AV; Radulovic S; Milovanovic S; Szepeshazi K; Isaacs JT
    Cancer Res; 1992 May; 52(9):2538-44. PubMed ID: 1568223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of microcapsules of luteinizing hormone-releasing hormone antagonist SB-75 and somatostatin analog RC-160 on endocrine status and tumor growth in the Dunning R-3327H rat prostate cancer model.
    Yano T; Pinski J; Szepeshazi K; Milovanovic SR; Groot K; Schally AV
    Prostate; 1992; 20(4):297-310. PubMed ID: 1351672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Decapeptyl (D-Trp6-LH-RH) in the therapy of prostatic cancer with reference to the intramuscular administration of a depot preparation].
    Seppelt U; Bertermann H; Saerbeck C
    Urologe A; 1986 Sep; 25(5):298-301. PubMed ID: 2947371
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radioimmunoassay for 6-D-tryptophan analog of luteinizing hormone-releasing hormone: measurement of serum levels after administration of long-acting microcapsule formulations.
    Mason-Garcia M; Vigh S; Comaru-Schally AM; Redding TW; Somogyvari-Vigh A; Horvath J; Schally AV
    Proc Natl Acad Sci U S A; 1985 Mar; 82(5):1547-51. PubMed ID: 3156381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Responses to the antagonistic analog of LH-RH (SB-75, Cetrorelix) in patients with benign prostatic hyperplasia and prostatic cancer.
    Gonzalez-Barcena D; Vadillo-Buenfil M; Gomez-Orta F; Fuentes Garcia M; Cardenas-Cornejo I; Graef-Sanchez A; Comaru-Schally AM; Schally AV
    Prostate; 1994; 24(2):84-92. PubMed ID: 7508623
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Treatment of precocious puberty with LH-RH agonists. Multicenter study using D-Trp-6-LH-RH in a programmed-release form].
    Roger M; Chaussain JL; Bost M; Bozzola M; Colle M; Despert F; François R; Freycon F; Garandeau P; Malpuech G
    Rev Fr Gynecol Obstet; 1986 May; 81(5):297-305. PubMed ID: 2943013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination of long-acting microcapsules of the D-tryptophan-6 analog of luteinizing hormone-releasing hormone with chemotherapy: investigation in the rat prostate cancer model.
    Schally AV; Redding TW
    Proc Natl Acad Sci U S A; 1985 Apr; 82(8):2498-502. PubMed ID: 3157990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversible inhibition of testicular androgen secretion by 3-, 5- and 6-month controlled-release microsphere formulations of the LH-RH agonist [D-Trp6, des-Gly-NH10(2)] LH-RH ethylamide in the dog.
    Lacoste D; Labrie F; Dubé D; Bélanger A; Tice T; Gilley RM; Pledger KL
    J Steroid Biochem; 1989 Nov; 33(5):1007-11. PubMed ID: 2689791
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of prostatic cancer with a depot form of a luteinizing hormone-releasing hormone analogue.
    Giuliani L; Barreca T; Giberti C; Franceschini R; Martorana G; Brancadoro MT; Salvemini M; Rolandi E
    Eur Urol; 1986; 12(6):390-4. PubMed ID: 2949979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.